Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases | Zendy

Erin M. Kim | Zendy; Cara Randall | Zendy; Renée Betancourt | Zendy; Staci Keene | Zendy; Amy Lilly | Zendy; Mark R. Fowler | Zendy; Evan S. Dellon | Zendy; Hans Herfarth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases

Author(s) -

Erin M. Kim,

Cara Randall,

Renée Betancourt,

Staci Keene,

Amy Lilly,

Mark R. Fowler,

Evan S. Dellon,

Hans Herfarth

Publication year - 2019

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izz251

Subject(s) - vedolizumab , medicine , eosinophil , gastroenterology , ulcerative colitis , eosinophilia , inflammatory bowel disease , immunology , disease , asthma

Peripheral and mucosal eosinophilia may be associated with more aggressive disease in inflammatory bowel disease (IBD) patients. Vedolizumab blocks T lymphocytes, eosinophil adhesion, and extravasation in the gastrointestinal tract. It is not known if mucosal eosinophilia is a predictor for the therapeutic efficacy of vedolizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research